- 3 hrs ago Daily Horoscope: 23 January 2020
- 11 hrs ago Can You Get Pregnant While On Birth Control Pills?
- 12 hrs ago 11 Health Benefits Of Doing Pushups Daily
- 13 hrs ago Did You Know These Benefits of Drinking Green Tea Before Bed
- News Democracy Index 2019: India slips 10 points to 51st Rank due to 'Erosion of civil Liberties'
- Technology Xiaomi Mi Motion Activated Night Light 2 Launched At Rs. 599 In India
- Movies Ala Vaikunthapuramloo Day 11 Worldwide Box Office: Film Maintains A Winning Streak
- Sports Tottenham 2-1 Norwich City: Son to the rescue as Mourinho's men fail to impress
- Finance Budget 2020: Govt May Tweak 5% Tax Slab To Include Upto Rs 7 Lakh Income
- Automobiles MG ZS Electric SUV Registers 2,800 Units In Bookings Within 27 Days Of Unveil
- Travel 10 Best Places To Visit In Jammu and Kashmir In 2020
- Education IIM Bangalore Women In Leadership Course Tanmatra
Menstrual cramps, also known as dysmenorrhea, creates several problems which include the pain in abdomen and back, nausea, mood swings, vomiting, sweating, and dizziness for ninety percent of the women. Menstrual cramps are caused by contractions of the uterus during menstruation. In dysmenorrhea, the uterus contracts with increased frequency, causing unusually severe, cramping pain. The reason for this is the increased blood levels of the hormone Vasopressin, which plays a role in regulating contraction of the uterus. The newly developed drug helps blocking the hormones, which can relieve dysmenorrhea.
Existing treatments for the condition include pain-relievers, anti-inflammatory drugs, and oral contraceptives that stop menstruation. These treatments are ineffective in almost one-third of women with moderate to severe cases. Some of them relieve only the symptoms, rather than targeting the underlying cause of dysmenorrhea, and may have unwanted side effects such as mood alteration and stomach upsets.
The newly developed drug, VAIII913, can fine tune the effects of dysmenorrhea. This drug is to be administered orally as a pill, rather than an injection. The drug is safe, with no apparent ill effects.
The next phase of clinical trials is currently underway in the U.K. and the U.S. to evaluate how well it works to control pain in a group of women with dysmenorrhea.
Investigators expect results to be available later this year. If studies continue to show promise, the drug could be available to patients in four years, says the scientists.